SAGE Therapeutics (SAGE) Misses Q2 EPS by 6c
Tweet
Share
E-mail
Get Alerts SAGE Hot Sheet
Join SI Premium – FREE
SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($1.70), $0.06 worse than the analyst estimate of ($1.64). Revenue for the quarter came in at $8.65 million versus the consensus estimate of $8.75 million.
For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters
- AI/ML Innovations plans $2M private placement on the CSE
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
